Top

Published in:

Open Access 01-12-2016 | Research

An observational study of adult admissions to a medical ICU due to adverse drug events

Authors: Pierre-Alain Jolivot, Claire Pichereau, Patrick Hindlet, Gilles Hejblum, Naïke Bigé, Eric Maury, Bertrand Guidet, Christine Fernandez

Published in: Annals of Intensive Care | Issue 1/2016

Abstract

Background

The objectives of the study were to estimate the incidence of intensive care unit (ICU) admissions due to adverse drug events (ADEs), to assess preventability, severity and costs of the corresponding ADE and to determine the leading causes of preventable ADEs.

Methods

An observational study was conducted in a medical ICU of a teaching hospital from February 2013 to February 2014.

Results

A total of 743 consecutive admissions were included, and they involved 701 different patients. The included admissions were categorized into three groups (admissions due to preventable ADE, admissions due to unpreventable ADE and the control group). Among the 743 ICU admissions included during the study period, 173 (23.3 %) were due to ADE, with 102 (13.7 %) related to preventable ADE and 71 (9.6 %) to unpreventable ADE, yielding a preventability rate of ADE of 0.59 (102/173). Admissions due to unpreventable ADE concerned patients with more comorbidities, a greater number of drugs and higher Simplified Acute Physiology Score II than admissions due to preventable ADE and the control group admissions (n = 570). Hospital mortality rates, corresponding costs and length of stay were all similar in the preventable ADE and control groups, whereas they were always significantly higher in the unpreventable ADE group. ICU mortality, length of stay and the corresponding costs were similar in the three groups. Non-compliance was the principal leading cause of preventable ADE (n = 31/102). The 102 preventable ADE-related admissions accounted for a total of 528 days of hospitalization in the ICU, requiring a mean of 1.4 ICU beds per day over the one-year period, with an associated total cost amounting to 747,651 €.

Conclusions

ADE was a major cause of admission in the studied ICU, and in 59 % of the cases, ADEs were preventable. The reported burden of ICU admissions due to ADE advocates for further investigations to explore how the rate of such admissions could be decreased.

Available only for authorised users

Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour Z. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol. 2014;78(2):202–17. doi:10.1111/bcp.12293.PubMedCentralCrossRefPubMed

Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25. doi:10.1345/aph.1L037.CrossRefPubMed

Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795–801.CrossRefPubMed

World Health Organization. The importance of pharmacovigilance—safety monitoring of medical products. 2002. http://apps.who.int/medicinedocs/en/d/Js4893e/. Accessed 24 Sept 2014.

Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280(11):1000–5.CrossRefPubMed

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301–6.CrossRefPubMed

Trunet P, Borda IT, Rouget AV, Rapin M, Lhoste F. The role of drug-induced illness in admissions to an intensive care unit. Intensive Care Med. 1986;12(1):43–6.CrossRefPubMed

Anonymous. Epidemiology of adverse drug reactions in intensive care units. A multicentre prospective survey. Italian Group on Intensive Care Evaluation (IGICE). Eur J Clin Pharmacol. 1987;31(5):507–512.

Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy. 1996;16(4):701–7.PubMed

10.

Darchy B, Le Miere E, Figueredo B, Bavoux E, Domart Y. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med. 1999;159(1):71–8.CrossRefPubMed

11.

Hammerman H, Kapeliovich M. Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. Isr Med Assoc J. 2000;2(8):577–9.PubMed

12.

Lehmann LS, Puopolo AL, Shaykevich S, Brennan TA. Iatrogenic events resulting in intensive care admission: frequency, cause, and disclosure to patients and institutions. Am J Med. 2005;118(4):409–13. doi:10.1016/j.amjmed.2005.01.012.CrossRefPubMed

13.

Grenouillet-Delacre M, Verdoux H, Moore N, Haramburu F, Miremont-Salame G, Etienne G, et al. Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med. 2007;33(12):2150–7. doi:10.1007/s00134-007-0787-8.CrossRefPubMed

14.

Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm. 2007;64(17):1840–3. doi:10.2146/ajhp060641.CrossRefPubMed

15.

Schwake L, Wollenschlager I, Stremmel W, Encke J. Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Med. 2009;35(2):266–74. doi:10.1007/s00134-008-1250-1.CrossRefPubMed

16.

Mercier E, Giraudeau B, Ginies G, Perrotin D, Dequin PF. Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med. 2010;36(6):1033–7. doi:10.1007/s00134-010-1793-9.CrossRefPubMed

17.

Nazer LH, Eljaber R, Rimawi D, Hawari FI. Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract. 2013;19(4):298–304. doi:10.1177/1078155212465995.CrossRefPubMed

18.

Garry DA, McKechnie SR, Culliford DJ, Ezra M, Garry PS, Loveland RC, et al. A prospective multicentre observational study of adverse iatrogenic events and substandard care preceding intensive care unit admission (PREVENT). Anaesthesia. 2014;69(2):137–42. doi:10.1111/anae.12535.CrossRefPubMed

19.

Jolivot PA, Hindlet P, Pichereau C, Fernandez C, Maury E, Guidet B, et al. A systematic review of adult admissions to ICUs related to adverse drug events. Crit Care. 2014;18(6):643. doi:10.1186/s13054-014-0643-5.PubMedCentralCrossRefPubMed

20.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.PubMed

21.

World Health Organization. International statistical classification of diseases and related health problems 10th revision. 2015. http://apps.who.int/classifications/icd10/browse/2016/en. Accessed 25 Nov 2015.

22.

Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957–63.CrossRefPubMed

23.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22(7):707–10.CrossRefPubMed

24.

MCCabe WRJ, Jackson GGEE. Gram negative bacteria. Etiology and ecology. Arch Intern Med. 1962;110:847–52.CrossRef

25.

Bittner MI, Donnelly M, van Zanten AR, Andersen JS, Guidet B, Trujillano Cabello JJ, et al. How is intensive care reimbursed? A review of eight European countries. Ann Intensive Care. 2013;3(1):37. doi:10.1186/2110-5820-3-37.PubMedCentralCrossRefPubMed

26.

World Health Organization. WHO collaborating centre for drug statistics methodology ATC classification system. 2013. http://www.whocc.no/atc_ddd_index/. Accessed 24 Sept 2014.

27.

Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40(2):111–8.PubMed

28.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed

29.

Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21(3):247–54.CrossRefPubMed

30.

Agresti AC, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat. 1998;52(2):119–26.

31.

Cohen J. A coefficient of agreement for nominal scale. Educ Psychol Meas. 1960;20(1):37–46.CrossRef

32.

Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother. 2005;39(11):1823–7. doi:10.1345/aph.1G177.CrossRefPubMed

33.

Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Saf. 2012;35(8):645–53. doi:10.2165/11599730-000000000-00000.CrossRefPubMed

34.

Reshef A, Stocchi L, Kiran RP, Flechner S, Budev M, Quintini C, et al. Case-matched comparison of perioperative outcomes after surgical treatment of sigmoid diverticulitis in solid organ transplant recipients versus immunocompetent patients. Colorectal Dis. 2012;14(12):1546–52. doi:10.1111/j.1463-1318.2012.03077.x.CrossRefPubMed

35.

Marquet K, Claes N, De Troy E, Kox G, Droogmans M, Schrooten W, et al. One fourth of unplanned transfers to a higher level of care are associated with a highly preventable adverse event: a patient record review in six Belgian hospitals. Crit Care Med. 2015;43(5):1053–61. doi:10.1097/CCM.0000000000000932.PubMedCentralCrossRefPubMed

36.

Agence nationale de sécurité du médicament et des produits de santé. Analyse des ventes de médicaments en France en 2013. 2013. http://ansm.sante.fr/var/ansm_site/storage/original/application/3df7b99f8f4c9ee634a6a9b094624341.pdf. Accessed 12 Dec 2014.

37.

Heaton PC, Tundia NL, Luder HR. U.S. emergency departments visits resulting from poor medication adherence: 2005–07. J Am Pharm Assoc. 2013;53(5):513–9. doi:10.1331/JAPhA.2013.12213.CrossRef

38.

Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. doi:10.1002/14651858.CD000011.pub4.PubMed

Title: An observational study of adult admissions to a medical ICU due to adverse drug events
Authors: Pierre-Alain Jolivot
Claire Pichereau
Patrick Hindlet
Gilles Hejblum
Naïke Bigé
Eric Maury
Bertrand Guidet
Christine Fernandez
Publication date: 01-12-2016
Publisher: Springer Paris
Published in: Annals of Intensive Care / Issue 1/2016
Electronic ISSN: 2110-5820
DOI: https://doi.org/10.1186/s13613-016-0109-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

An observational study of adult admissions to a medical ICU due to adverse drug events

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Glutamine, fish oil and antioxidants in critical illness: MetaPlus trial post hoc safety analysis

Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis

A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring

Designing and conducting a cluster-randomized trial of ICU admission for the elderly patients: the ICE-CUB 2 study

Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)

Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis